Assembly Biosciences
Yanhong (Yan) Zhu is a seasoned toxicology professional with extensive experience in the pharmaceutical industry. Currently serving as the Senior Director of Toxicology at Assembly Biosciences, Inc. since April 2022, Yanhong has also held the position of Senior Director of Therapeutic Development at Atreca, Inc. since September 2018. Previous roles include Director of Toxicology at Dermira, Inc., and Principal Scientist in Toxicology/Drug Safety Evaluation at Bristol-Myers Squibb. Yanhong's career highlights include significant contributions to global preclinical safety programs across various therapeutic areas, representing the Global Preclinical Safety department in multiple multidisciplinary teams. Yanhong holds a Master's degree in Pathology from Tongji Medical University and a Doctor of Medicine (M.D.) from Anhui Medical University.
This person is not in any teams
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.